Home › Compare › YNAJF vs ABBV
YNAJF yields 3.16% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, YNAJF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YNAJF + ABBV for your $10,000?
Yantai North Andre Juice Co., Ltd. manufactures and sells various fruit and vegetable juices, fruit pulp, essence, pomace, biological feed, and related products in China. It also manufactures fruit and vegetable beverages, apple juice concentrate, pear juice concentrate, peach puree and juice, haw juice concentrate, sweet potato juice concentrate, strawberry puree and juice concentrate, apple fructose, pear fructose, drinking water, cloudy apple juice, and other products. In addition, the company manufactures iron drums for juice outer packaging; purchases agricultural and sideline products; imports and exports goods and technology; and manufactures and sells of lemon and orange juice, lemon oil and essence, and orange oil and essence. Further, it is involved in the biological comprehensive utilization of apple essence, pomace, vegetables, and other products; import and export of juice and pulp; and provision of goods storage services. The company also exports its products to rest of Asia, Europe, North America, Africa, Oceania, and South America. The company was founded in 1996 and is headquartered in Yantai, the People's Republic of China.
Full YNAJF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.